Kardi Trading Private Limited

Kardi Trading Private Limited is a privately held pharmaceutical export company based in Hyderabad, Telangana, India. Established on December 10, 2018, the company operates under the Corporate Identification Number (CIN) U51909TG2018PTC128909. The registered office is located at H.No.8-3-940 & 940/A to E, Tirumala Shah Residency, Yellareddyguda Ameerpet, Hyderabad, Telangana, 500073. Kardi Trading specializes in the wholesale trading of pharmaceutical formulations, including tablets, capsules, syrups, and injections.

The company has demonstrated significant growth in recent years. In the financial year ending March 31, 2024, Kardi Trading reported a 31.98% increase in total revenue compared to the previous year. Profitability also improved, with a 64.1% increase in profit. The net worth of the company saw a substantial rise of 103.38% during the same period. As of the latest available data, the authorized capital stands at ₹1.00 million, with a paid-up capital of ₹0.10 million.

Kardi Trading Private Limited operates its manufacturing facilities in Hyderabad, Telangana, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding the manufacturing plant locations, capacities, and specializations are not publicly disclosed. However, the company's significant export activities and product portfolio suggest a well-established manufacturing infrastructure capable of meeting international standards.

The leadership team of Kardi Trading Private Limited comprises two directors:

• Sai Vishwajeet Shaw: Serving as a director since the company's inception on December 10, 2018.

• Ramchandraiah Metthati: Also appointed as a director on December 10, 2018.

Both directors have been associated with the company for over seven years, indicating a stable leadership structure. Additional details regarding other key executives are not publicly available.

Kardi Trading Private Limited's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's trade data indicates a significant presence in various international markets, with a total export value of $9.2 million USD across 363 shipments. The top five exported products include:

• Semaglutide: $1.2 million USD, accounting for 24.3% of the market share.

• Protein: $2.1 million USD, with a 14.0% market share.

• Carboplatin: $2.6 million USD, representing 3.7% of the market share.

• Paclitaxel: $2.4 million USD, holding a 2.9% market share.

• Sofosbuvir: $312,000 USD, comprising 0.8% of the market share.

The therapeutic categories with the highest export values are:

• Oncology: 55.1%

• Nutritional Supplements: 22.5%

• Advanced Diabetes Medications: 13.1%

While specific regulatory filings and approvals in the US, EU, UK, Australia, and Japan are not publicly disclosed, the company's substantial export activities suggest compliance with international regulatory standards. The focus on finished pharmaceutical formulations indicates adherence to Good Manufacturing Practices (GMP) and other relevant regulations in these markets.

Kardi Trading Private Limited has demonstrated a strong presence in emerging markets, particularly in Africa, Latin America, and Southeast Asia. The company's export data reflects a diversified portfolio across these regions, with significant contributions from products like Semaglutide and Protein. The WHO prequalification of certain products may have facilitated access to these markets, enhancing the company's credibility and acceptance among international buyers.

Kardi Trading's export data reveals a diversified geographic strategy, with significant market shares in various regions. The company's top five products account for 94.1% of its total export value, indicating a focused product portfolio. This concentration suggests a strategic emphasis on high-demand products, potentially reducing the risk associated with market diversification. The company's substantial presence in oncology, nutritional supplements, and advanced diabetes medications aligns with global health trends, positioning Kardi Trading favorably in these therapeutic areas.

Specific details regarding Kardi Trading Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's substantial export activities and focus on finished pharmaceutical formulations suggest compliance with international regulatory standards, including those set by the FDA. The emphasis on high-demand products like Semaglutide and Protein indicates adherence to stringent quality and regulatory requirements.

While specific certifications such as WHO prequalification and EU GMP certificates are not publicly disclosed, Kardi Trading's significant export activities and focus on finished pharmaceutical formulations imply adherence to international quality standards. The company's product portfolio, including oncology and advanced diabetes medications, suggests compliance with Good Manufacturing Practices (GMP) recognized by global regulatory bodies.

Kardi Trading Private Limited operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed. However, the company's substantial export activities and focus on finished pharmaceutical formulations indicate compliance with CDSCO regulations and other relevant Indian regulatory requirements.

There are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Kardi Trading Private Limited. The company's substantial export activities and focus on finished pharmaceutical formulations suggest adherence to international regulatory standards and a commitment to quality.

Kardi Trading Private Limited operates in a competitive pharmaceutical export market, with several key players in overlapping therapeutic categories. The company's top five products—Semaglutide, Protein, Carboplatin, Paclitaxel, and Sofosbuvir—are in high-demand therapeutic areas, indicating a competitive positioning. While specific market share comparisons and head-to-head analyses are not publicly available, Kardi Trading's focus on high-demand products and diverse therapeutic categories suggests a strategic approach to capturing market share.

Kardi Trading's key differentiators include a focused product portfolio with high-demand products like Semaglutide and Protein, a diversified presence across multiple therapeutic categories, and a significant export footprint in emerging markets. The company's emphasis on finished pharmaceutical formulations indicates a commitment to quality and compliance with international regulatory standards.

Kardi Trading Private Limited's current strategic direction appears to be centered on exporting high-demand finished pharmaceutical formulations across diverse therapeutic categories. The company's significant presence in oncology, nutritional supplements, and advanced diabetes medications aligns with global health trends, positioning Kardi Trading favorably in these markets. The focus on emerging markets suggests a strategy to leverage growth opportunities in regions with increasing healthcare needs.

Kardi Trading Private Limited has demonstrated a strong track record in pharmaceutical exports, with a total export value of $9.2 million USD across 363 shipments. The company's focus on finished pharmaceutical formulations indicates a commitment to quality and compliance with international standards. The substantial presence in oncology, nutritional supplements, and advanced diabetes medications suggests reliability in meeting market demands.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration. Verification can be done through the FDA's official website or by contacting the manufacturer directly.

• WHO-GMP Certification: Ensure that the manufacturing facilities comply with World Health Organization's Good Manufacturing Practices. This can be verified by checking the WHO's official prequalification list.

• EU GMP Certification: Verify that the products meet European Union Good Manufacturing Practices. This information is typically available through the European Medicines Agency (EMA) or the manufacturer's documentation.

• ISO Certification: Check for ISO certifications related to quality management systems. These can be verified through the International Organization for Standardization's